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Abstract
 
Few hepatitis C virus (HCV) infections resolve spontaneously but those that do appear to afford
protective immunity. Second infections are usually shorter in duration and are less likely to
persist but mechanisms of virus control in immune individuals have not been identified. In this
study we investigated whether memory helper and/or cytotoxic T lymphocytes provide pro-
tection in chimpanzees serially reinfected with the virus. Clearance of the first infection took
 
3–4 mo and coincided with the delayed onset of CD4
 
 
 
 and CD8
 
 
 
 T cell responses. High fre-
quencies of memory T cells targeting multiple HCV proteins were stable over 7 yr of follow-up.
Animals were infected for a second time to assess the protective role of memory T cells. In
contrast to the prolonged course of the first infection, viremia was terminated within 14 d.
Control of this second infection was kinetically linked to rapid acquisition of virus-specific cy-
tolytic activity by liver resident CD8
 
 
 
 T cells and expansion of memory CD4
 
 
 
 and CD8
 
 
 
 T
cells in blood. The importance of memory CD8
 
 
 
 T cells in control of HCV infection was
confirmed by antibody-mediated depletion of this lymphocyte subset before a third infection.
Virus replication was prolonged despite the presence of memory CD4
 
 
 
 T helper cells primed
by the two prior infections and was not terminated until HCV-specific CD8
 
 
 
 T cells recov-
ered in the liver. These experiments demonstrate an essential role for memory CD8
 
 
 
 T cells in
long-term protection from chronic hepatitis C.
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Introduction
 
Primary hepatitis C virus (HCV)
 
*
 
 infection resolves spon-
taneously in some individuals but most develop a persistent
viremia that is often associated with progressive liver dis-
ease over a period of years to decades (1). A substantial
body of evidence indicates that cellular immune responses
are involved in control of the infection (2–6). Virus clear-
ance in humans and chimpanzees has been linked in most
studies to the onset of sustained HCV-specific CD4
 
 
 
 and
CD8
 
 
 
 T cell responses (2–6) and an increase in IFN-
 
 
 
mRNA levels in the liver (2). In contrast, cellular immune
responses fail in those who develop persistent infections (2–
6). HCV-specific CD4
 
 
 
 T cells are absent or transiently
present in the blood (2, 4, 5, 7, 8), do not accumulate in
substantial numbers in the liver (2), and may be skewed
toward production of regulatory rather than antiviral cy-
 
tokines (9). CD8
 
 
 
 T cells are sometimes detected in per-
sistently infected humans and chimpanzees but they may
lack adequate effector function (4, 5, 10–13), target a lim-
ited repertoire of viral epitopes (3, 5), and rapidly select for
viruses that contain MHC class I escape mutations (14–16).
Despite this circumstantial evidence linking the outcome of
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*
 
Abbreviations used in this paper:
 
 CID, chimpanzee infectious doses; GE,
genome equivalents; HCV, hepatitis C virus; IHL, intrahepatic lympho-
cyte
 
; 
 
SFC, spot forming cell.T
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HCV infection with the strength of cellular immune re-
sponses, the effector mechanisms and the relative impor-
tance of CD4
 
 
 
 versus CD8
 
 
 
 T cells in prevention of per-
sistence, are still unknown.
Individuals who successfully resolve primary HCV infec-
tions appear to have robust immunity against the virus be-
cause subsequent infections rarely persist (17). Studies in
chimpanzees have revealed that the duration of viremia is
also shortened after a second infection (18–22). So far this
animal model has provided limited insight into the nature
of protective immune responses. Resolution of a second
infection was associated with a rapid type I IFN response in
one study (21) and IFN-
 
 
 
 in another (22). Involvement of
memory CD4
 
 
 
 and/or CD8
 
 
 
 T cells has not been estab-
lished. Primed memory T cells were not detected in chim-
panzees with resolved HCV infections (20–23). Moreover,
after reinfection virus-specific lymphoproliferative responses
were very weak or not consistently detected in all animals
(20–22) so a temporal relationship between rapid clearance
of virus and accelerated T cell responses has not been estab-
lished.
Here we report that memory CD8
 
 
 
 T lymphocytes are
required to rapidly terminate HCV replication upon reex-
posure to the virus. In a series of three infections in chim-
panzees we demonstrate that (a) memory CD4
 
 
 
 and CD8
 
 
 
T cell frequencies are set immediately after resolution of
primary HCV infection and then do not vary over a period
of several years, (b) the duration and peak of viremia are
substantially diminished after a second infection and this
control is temporally associated with a rapid and massive
expansion of fully functional memory helper and cytotoxic
T cells, and (c) antibody-mediated depletion of the cyto-
toxic CD8
 
 
 
 subset immediately before a third infection re-
sulted in a prolonged course of viremia that was not termi-
nated until memory CD8
 
 
 
 T cells recovered in the liver.
 
Materials and Methods
 
HCV Infections.
 
Chimpanzees (Pan troglodytes) were main-
tained under standard conditions for humane care and in compli-
ance with NIH guidelines at the New Iberia Research Center,
Lafayette, LA. They were infected intravenously with 100 chim-
panzee infectious doses (CID) of HCV-1/910 stock (24) and
then rechallenged 7 yr later with the same virus. 6 mo after clear-
ance of the second infection, three doses of the anti-CD8 anti-
body cM-T807 (25, 26) were administered intravenously 14, 11,
and 7 d before a third HCV challenge with 100 CID of HCV-1/
910. An initial dose of 5 mg of cM-T807 per Kg body weight
was followed by two reinforcing doses of 2.5 mg/Kg.
 
HCV RNA.
 
HCV RNA levels in frozen plasma collected in
EDTA were analyzed by HCV 3.0 RNA branched DNA (bDNA;
sensitivity 3,500 genome equivalents [GE]/ml) and HCV RNA
TMA QL (sensitivity 50 GE/ml) assays by Bayer Diagnostics.
 
HCV Antibody Titers.
 
HCV-specific antibody titers in serum
were measured using a multi-antigen ELISA as described previ-
ously (27, 28). Assay cut off was the mean O.D. of plasma from
HCV seronegative humans 
 
 
 
 7 standard deviations. Relative
units of antibody titers were determined as O.D. of sample mul-
tiplied by the dilution factor. Serum titers are expressed as:
 
(
 
   
 
) 
 
 
 
1,000, (
 
  
 
) 100–1,000, (
 
 
 
) 10–100, (
 
 
 
/
 
 
 
) 
 
 
 
10 and
(–) undetectable.
 
Isolation of Lymphocytes from Blood and Liver.
 
PBMCs were
isolated using Ficoll density gradient. To recover intrahepatic
lymphocytes (IHL), liver biopsies were gently homogenized in
PBS containing 1% FCS, CD8
 
 
 
 T cells were enriched using
anti–human CD8
 
 
 
 dynabeads (Dynal) and expanded using anti-
human CD3 antibodies (Immunotech) as described previously (3,
29). Expanded cells were tested in either CTL or IFN-
 
 
 
ELISPOT assays. For direct tetramer staining, liver homogenate
was filtered through 70 
 
 
 
 cell strainers and stained directly with-
out in vitro expansion as described below.
 
Liver CTL Assays.
 
CD8
 
 
 
 T cells expanded from liver were
tested for HCV-specific cytotoxic activity in a standard 4 h 
 
51
 
Cr
release assay as described previously (3, 29). Target cells were au-
tologous EBV-transformed B cell lines infected with HCV-1 re-
combinant vaccinia vectors (a kind gift of Chiron Corporation,
Emeryville, CA) that span the following regions: vv core/E1
(amino acids [aa]: 1–384), vv E2-NS3 (aa: 364–1618), vv NS4
(aa: 1590–2050), vv NS5A (aa: 2005–2396), and vv NS5B (aa:
2396–3011). Specific killing greater than 10% of prechallenge
baseline at two E:T ratios was considered positive.
 
ELISPOT Assay.
 
Nine pools containing 30–40 peptides
each were prepared using a set of 301 overlapping peptides
(Mimotopes Pty) encompassing the entire HCV-1 polyprotein
according to the published sequence by Choo et al. (24). Peptides
were 20 amino acids long overlapping by 10 residues. Human
IFN-
 
 
 
 ELISPOT kits were purchased from U-cytech. Cryopre-
served PBMCs were used to assay the immune response during
primary infection. Freshly isolated PBMCs were used in the sec-
ondary and tertiary infections. Comparison of T cell frequencies
post primary infection using fresh and frozen PBMCs collected at
the same time point yielded comparable results. 1–2 
 
 
 
 10
 
5
 
PBMCs were cocultured in duplicate in round bottom 96-well
plates with peptide pools for 40–48 h at 0.5 
 
 
 
g/ml final concen-
tration of each peptide in Aim-HS (Aim-V lymphocyte media
[Invitrogen] supplemented with 2% human AB serum [Gemini-
BioScience]). PBMCs were then transferred to precoated
ELISPOT plates, incubated at 37
 
 
 
C for 16–18 h and then devel-
oped according to the manufacturer’s protocol. The ovalbumin
derived peptide “SIINFEKL” was used as a negative control. Num-
ber of specific spots was calculated by subtracting the mean num-
ber of spots in negative control duplicates from the mean number
of spots in test duplicates, then normalized to number of specific
spots/10
 
6
 
 PBMCs. In some assays, CD8
 
 
 
 T cells were removed
from PBMCs using paramagnetic beads (Dynal), and the cells in-
corporated in the assay as outlined above.
CD8
 
 
 
 IHLs were isolated and expanded from liver biopsies as
described above. For the ELISPOT assay, 10
 
5
 
 irradiated autolo-
gous PBMCs were used as antigen presenting cells with 0.5–1 
 
 
 
10
 
5
 
 expanded intrahepatic CD8
 
 
 
 T cells for 40–48 h then pro-
cessed for spot formation as outlined above.
 
Flow Cytometry.
 
Antibodies used included anti–human CD3,
CD4 (Leu 3a), CD8-PerCP (Leu-2a), CD28 (CD28.2), CD49d
(9F10), IFN-
 
 
 
–FITC (4S.B3), and CD69-APC (L78) all from
BD Biosciences. Patr B2301/E2
 
445
 
 tetramer was synthesized at
the NIH tetramer core facility, Emory University, Atlanta, GA.
Cryopreserved PBMCs were used to assay the frequency of
tetramer
 
 
 
 cells during primary infection. Freshly isolated PBMCs
were used in the secondary and tertiary infections. 10
 
6
 
 fresh or
frozen PBMCs in AIM-HS medium were used per stain. For in-
tracellular cytokine staining, cells were first stimulated with E2
 
445
 
peptide (1 
 
 
 
g/ml) for 6 h at 37
 
 
 
C in presence of anti-CD28 andT
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CD49d (1 
 
 
 
g/ml each) and addition of Brefeldin A (10 
 
 
 
g/ml)
after the first hour. The reaction was stopped by resuspension in
FACS buffer (PBS, 2% FCS, 0.1% NaN3). Cells were then
stained with anti-CD8 antibody for 20 min at 4
 
 
 
C, followed by
the tetramer for 30 min at room temperature, permeabilized us-
ing cytofix-cytoperm solution (BD Biosciences), and finally
stained with anti-IFN-
 
 
 
–FITC and CD69-APC for 30 min at
4
 
 
 
C. Cells were resuspended in 4% formaldehyde solution and
analyzed on a FACSCalibur™ instrument using CELLQuest™
software. 100,000 events were acquired in the CD8
 
 
 
 T lympho-
cytes gate. For direct tetramer staining on liver homogenate,
10,000–15,000 events were acquired.
Depletion of T cell subsets in the peripheral blood after cM-
T807 treatment was monitored by 4 color flow cytometry using
anti-CD3 and subset-specific antibodies against CD4 (Leu 3a)
and CD8 (DK25) (DakoCytomation), an antibody previously
shown to bind CD8 protein in presence of cM-T807 (25).
 
Results
 
Primary Infection
Virus Replication and Immune Responses.
 
Chimpanzees
CB0556 and CB0572 were enrolled in a vaccine study by
Chiron Corporation in 1994. Recombinant envelope gly-
coproteins E1 and E2 produced in Chinese hamster ovary
(CHO) cells were used to vaccinate the animals 3 times be-
fore challenge with 100 CID of the HCV-1/910 virus in-
oculum. Serum antibodies against E1 and E2 on the day of
virus challenge did not protect them from infection. They
exhibited a prolonged course of viremia that lasted for 3
(CB0572) or 4 (CB0556) mo (Fig. 1, A and B). An identi-
cal pattern of viremia and clearance was observed in a
mock-vaccinated control animal (unpublished data).
We next examined the relationship between control of
viral infection and T cell–mediated immune responses us-
ing an IFN-
 
 
 
 ELISPOT assay with pooled peptides that
spanned the HCV polyprotein. A weak vaccine-induced
IFN-
 
 
 
 T cell response against the envelope glycoproteins
was observed in the blood of both animals before infection
but it rapidly disappeared by day 16 after infection when
HCV RNA was first detected in their plasma (Table I).
Over the next 2 wk virus titers increased to 
 
 
 
1 
 
 
 
 10
 
6
 
 GE/
ml of plasma and remained stable (CB0556) or increased
slightly (CB0572) until day 56 after infection when a sharp
alanine aminotransferase (ALT) increase and T cell re-
sponses against nonstructural proteins were detected for the
first time (Table I, and Fig. 1, A and B). These experiments
provided additional support for an infection model where
HCV replicates for weeks or months in the absence of
overt liver damage and clearance is associated with the on-
set of a sustained T cell response that can cause immunopa-
thology (2–4).
 
Evolution and Stability of Memory T Cell Populations.
 
We
observed an unexpected reduction in HCV-specific T cell
frequencies in the blood of both animals just as HCV infec-
tion was controlled. Strong cytotoxic T cell activity was
present in the liver at these time points (unpublished data),
suggesting that effector lymphocytes were localizing to the
liver. HCV-specific T cell frequencies rebounded 
 
 
 
1 mo
later to form a memory pool targeting multiple viral pro-
teins that did not wane over 7 yr of follow-up (Table I). In
contrast to the stability of memory T cells, serum antibod-
ies against the envelope glycoproteins induced by vaccina-
tion or infection were undetectable or present at very low
titers 7 yr later (Fig. 1, A and B).
Similar results were obtained by monitoring memory
CD8
 
 
 
 T cell frequencies against a Patr-B2301 restricted
epitope designated E2
 
445
 
 targeted by chimpanzee CB0572
(Table II). This epitope was identified in the liver and
blood of CB0572 at 6 yr after infection. Tetramer analysis
of cryopreserved PBMCs collected during the primary in-
Figure 1. Course of acute resolving HCV-1 infection in chimpanzees
CB0556 and CB0572. Virus replication and HCV-specific immune re-
sponses after primary infection of CB0556 (A) and CB0572 (B). HCV
RNA genome equivalents (GE) per milliliter of plasma (GE/ml) are
shown. Spot forming cells (SFCs) ( 10 3) represent the sum of responses
to pools of overlapping peptides. Day 2541 (7 yr) is representative of four
independent time points. (C) Detection of E2445-specific CD8  T cells
using IFN-  ELISPOT and a Patr B2301 tetramer during primary infec-
tion of CB0572.T
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fection demonstrated that this population first appeared in
blood at day 86 after infection and stabilized at a frequency
of 
 
 
 
0.14% of CD8
 
 
 
 PBMCs by month 5 after infection
that did not change over the next 7 yr (Fig. 1 C). Interest-
ingly, E2
 
445
 
-specific T cells visualized in blood with the
tetramer starting on day 86 after infection were not consis-
tently detected in the IFN-
 
 
 
 ELISPOT assay until day 121
after infection (Fig. 1 C), implying that this population
transiently lacked effector function as previously suggested
by others (4, 5, 10–13).
 
Secondary Infection
Virus Replication and Immune Responses.
 
Chimpanzees
CB0556 and CB0572 were rechallenged seven years after
the first infection with the identical strain and dose of HCV
to determine if these long-lived memory T cell responses
could blunt viral infection. HCV RNA peaked at 10
 
5
 
 GE/
 
Table I.
 
Diversity of the HCV-specific Response During Primary Infection
 
CB0556 CB0572
IFN-
 
 
 
 SFC/10
 
4
 
 PBMCs IFN-
 
 
 
 SFC/104 PBMCs
Day after
infection
HCV RNAa
(GE/ml plasma) Core-NS2 NS3 NS4 NS5
HCV RNAa
(GE/ml plasma) Core-NS2 NS3 NS4 NS5
0  2,500 275 0 0 0  2,500 130 0 0 0
16 1.6   105 0 0 0 0 1.4   105 00 0 0
30 9   105 00 0 0 1     106 00 0 0
56 8.8   105 250 735 450 195 4.4   106 95 570 100 0
71 ND 0 0 0 0 ND 100 1,130 405 165
86 4   103 00 0 0  2,500 0 375 0 0
99 ND 55 225 0 0 ND 95 195 130 0
121 ND 510 585 485 205 ND 800 1,385 475 935
149  2,500 560 595 570 0  2,500 625 905 380 590
205 ND ND ND ND ND ND 530 970 470 410
7 yrb  2,500 660 705 665 119  2,500 580 915 550 460
aDetermined by HCV-RNA 3.0 assay (sensitivity  2,500 GE/ml plasma).
bRepresentative data from four independent time points before secondary infection at 7 yr.
Figure 2. Virus replication and HCV-specific immune responses after
rechallenge with HCV-1 at 7 yr after primary infection IFN-  SFC after
a second infection of CB0556 (A) and CB0572 (B) represent the sum of
responses to pools of overlapping peptides or the individual CD8  T cell
epitopes P7756 (A) and E2445 (B). Prechallenge ELISPOT represents the
mean SFC/106 PBMC at four independent time points. Frequency of
E2445 specific T cells measured by tetramer staining is represented as per-
cent of CD8  T cells. (C) Detection of E2445-specific T cells using a Patr
B2301 tetramer. PBMCs from CB0556 (Patr B2301 ) (left panel) and
from CB0572 (Patr B2301 ) at  7 yr after the first infection (middle
panel) and at day 14 after the second infection (right panel) were stained
with E2445/Patr B2301 tetramer. A total of 100,000 events were acquired
in the CD8  lymphocyte gate and the frequency is presented as percent
of CD8  tetramer  T cells. (D) Peptide activation of E2445-specific T
cells from blood of CB0572 collected on day 14 after infection.T
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ml of plasma in both chimpanzees by day 7 after infection
and declined thereafter (Fig. 2, A and B). ALT increases
were mild compared with the first infection (unpublished
data). Antibody titers were boosted by the second infection
but only after the virus was permanently cleared from
plasma (unpublished data), so it is unlikely that they exerted
antiviral activity. Memory T cell frequencies detected by
an IFN-  ELISPOT assay did not increase through the first
10 d of infection. However, a 3–6 fold expansion was de-
tected at the next sampling point 4 d later when HCV
RNA levels were very low in CB0556 (64 GE/ml) and
undetectable in CB0572 (Fig. 2, A and B). This response
peaked on day 21 and was mediated by CD4  and CD8 
T cells because frequencies were reduced by 50% if CD8 
T cells were removed before the assay (unpublished data).
Involvement of HCV-specific CD8  T cells was confirmed
by monitoring responses against MHC class I–restricted
epitopes identified in the liver and/or the blood of each
chimpanzee before the secondary infection (Table II).
Memory CD8  T cells from CB0556 that recognized the
Patr-A0701 restricted epitope designated P7756 (Table II)
expanded more than 20-fold in blood between days 10 and
14 after infection (Fig. 2 A). T cells from CB0572 targeting
the E2445 epitope remained stable in blood at a frequency of
0.1% by IFN-  ELISPOT and MHC class I tetramer assays
through the first 10 d of the second infection. Remarkably,
they expanded 45-fold (to 4.5% by tetramer analysis) by
day 14 (Fig. 2, B and C) and were fully functional because
they expressed the activation marker CD69 and produced
IFN-  after in vitro peptide stimulation (Fig. 2 D). Fre-
quencies of HCV-specific cells in both chimpanzees de-
clined gradually to baseline values by day 94 after infection
(Fig. 2, A and B).
Intrahepatic CD8  T Cell Responses. Too few CD8  T
cells were recovered from typical liver specimens ( 104/
gram of tissue) to directly measure virus-specific popula-
tions so they were first expanded with anti-CD3 antibod-
ies. HCV-specific T cells were not detected in the liver of
either animal before reinfection using tetramer staining
(Fig. 3 A) or cytotoxicity assays (Fig. 3, B and C), probably
because they were present at a frequency too low to be
measured in uncloned, anti-CD3 expanded T cell popula-
tions. However, HCV-specific cytolytic activity was de-
tected in the liver of CB0572 and CB0556 by day 10 after
infection against autologous target cells expressing the E2-
P7-NS2-NS3 proteins (vv E2-NS3; Fig. 3, B and C). In
the case of CB0572, at least some of this cytolytic activity
on days 14 and 21 was directed against the E2445 epitope
because targets pulsed with the peptide epitope were killed
(Fig. 3 B) and a high percentage of the expanded CD8  T
cells stained with the Patr-B2301/E2445 tetramer (Fig. 3
A). Furthermore, the response broadened in both animals
on day 14 after infection to include targets expressing the
NS5B protein and returned to baseline values by day 44 af-
Figure 3. Intrahepatic HCV-specific responses
upon rechallenge with HCV-1. (A) Detection of
E2445 specific T cells using a Patr B2301 tetramer
on in vitro expanded CD8  T cells (IHL). CD8 
lymphocytes isolated from the liver of CB0572 at
the indicated time points were expanded with anti-
CD3 antibodies for 2–3 wk and stained with the
Patr B2301/E2445 tetramer. Frequency is presented
as percent of CD8  tetramer  T cells. Acquisition
of HCV-specific CTL activity by intrahepatic
CD8  T cells (IHL) isolated from CB0572 (B) and
CB0556 (C). Intrahepatic CD8  T cells expanded
with anti-CD3 antibodies were tested for cytolytic
activity against autologous B lymphoblastoid cell
lines infected with recombinant vaccinia viruses ex-
pressing all regions of the HCV polyprotein. Killing
was detected only against targets that expressed
E2-P7-NS2-NS3 (vvE2-NS3; aa 364–1618) and
NS5B (vvNS5B; aa 2396–3011) and targets pulsed
with the E2445 peptide. Cytolytic activity was
scored as positive (*) when it exceeded baseline (pre-
infection) values by 10% at two effector to target (E:T)
cell ratios. Data shown are for a 25:1 E:T ratio.T
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ter infection (Fig. 3, B and C). These results suggested that
intrahepatic CD8  T cells that gain cytolytic function
within a few days of infection contribute to rapid decline
in viremia.
Tissue Distribution of HCV-specific T Cells. Evidence for
selective retention of memory CD8  T cells in the liver af-
ter clearance of the second infection was obtained by com-
paring decay of E2445-specific CD8  T cells in blood and
liver without anti-CD3 antibody expansion. Two weeks
after clearance of infection (i.e., at day 28 after infection)
 4.5% of CD8  T cells in liver stained with the tetramer
compared with 1% in blood (Fig. 4 A). E2445-specific T
cells declined in both tissue compartments by 6 mo after
resolution of the second infection but were still  10 times
more concentrated in liver (1.8%) than blood (0.2%; Fig. 4
A). Interestingly, memory CD8  T cells in the liver but
not blood expressed the activation marker CD69 at multi-
ple time points during the six months follow-up period
(Fig. 4 B). This constitutively activated phenotype is iden-
tical to that of tissue-resident effector memory CD8  T
cells previously described in mice (30, 31).
Tertiary Infection
Antibody-mediated CD8  T Cell Depletion and the Course
of HCV Infection. We next assessed the importance of
memory CD8  T cells in control of HCV infection by
treating both animals with the anti-CD8 antibody cM-
T807 6 mo after resolution of the second infection. This
antibody was used successfully in rhesus monkeys (25) and
chimpanzees (26) to asses the role of CD8  T cells in con-
trol of simian immunodeficiency virus (SIV; reference 25)
and hepatitis B virus (HBV; reference 26) infections, re-
spectively. Three doses of cM-T807 were administered in-
travenously 14, 11, and 7 d before a third HCV challenge.
Prior to administration of the third antibody dose (day  7)
CD8  T cells were already undetectable in blood using a
monoclonal antibody (DK25) that does not compete with
cM-T807 for CD8 binding (25) and they remained at less
than 15% of baseline values through 6 mo of follow-up
(Fig. 5 A, Table III). CD4  T cell numbers were stable in
the blood of both animals (Fig. 5 A, Table III). 7 d after the
third dose of cM-T807 both animals were challenged for a
third time with 100 CID of HCV-1/910. HCV RNA was
first detected in the plasma of CB0556 at day 7 after infec-
tion and CB0572 at day 10 after infection (Table III, Fig. 5,
B and C), and peak titers were not substantially different
from those observed after the secondary infection when
CD8  T cell compartments were intact (Fig. 6). Impor-
tantly, HCV infection was prolonged by at least 3 wk in
both animals (Fig. 6). HCV RNA was consistently de-
tected in the plasma of CB0556 and CB0572 for 35 d after
the third infection (Table III, Fig. 5, B and C), and con-
trasts with the second infection where HCV RNA was de-
Table II. MHC Class I–restricted Epitopes Identified at 6 yr After Primary Infection
HCV protein Epitope designation Patr MHC restriction Amino acid coordinates Peptide sequence
CB0556 P7 P7756
a A0701 756–770 AASLAGTHGLVSFL
CB0572 E2 E2445
a, b B2301 445–457 HKFNSSGCPERL
NS5B NS52663
b B2401 2663–2673 CDLDPQARVAI
aIdentified in blood at 6 yr after primary infection.
bIsolated by limit dilution cloning from the liver at 6 yr after primary infection.
Figure 4. Tissue distribution and phenotype of Patr B2301/E2445 tet-
ramer-reactive CD8  T cells. Lymphocytes were isolated directly from
blood and liver of CB0572 at the indicated time points and stained (with-
out anti-CD3 antibody expansion) with anti-CD8 antibodies and Patr
B2301/E2445 tetramer (A). Cells were also stained with anti-CD69 anti-
bodies (B). 10,000–15,000 events were acquired in the CD8  T lympho-
cytes gate and frequency is represented as percent of CD8  tetramer 
cells (A) or percent of tetramer  CD69  cells (B).T
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tected in CB0556 through day 14 (at less than 100 GE/ml)
and in CB0572 through day 10 (Fig. 2, A and B).
Memory T cell frequencies were partially reduced in
both animals immediately after cM-T807 treatment. Im-
portantly, responses to the defined MHC class I–restricted
epitopes were lost entirely, reflecting the effectiveness of in
vivo CD8  T cell depletion (Table III). CD4  T cell fre-
quencies were unaffected by cM-T807 treatment because
they remained identical in both animals before (day –28)
and immediately after (day –7) antibody administration
(Table III). HCV-specific CD4  T cell frequencies de-
clined transiently in the blood of both animals when vire-
mia was first detected but they recovered to baseline values
by day 21 after infection, well before HCV RNA began to
decline in plasma (Table III), suggesting that this T cell
subset alone was not sufficient to rapidly clear the infection.
Resolution of HCV Infection Requires Intrahepatic CD8  T
Cells. After cM-T807 treatment and infection, the few
CD8  T cells that remained in blood failed to produce
IFN-  in response to HCV peptide pools and only tran-
siently against the dominant MHC class I–restricted epitope
P7756 in CB0556 on day 42 after infection (Table III). We
therefore postulated that HCV-specific CD8  T lympho-
cytes recovered in the liver before the blood and were re-
sponsible for control of plasma viremia.
CD8  T cells could not be expanded from the liver of
CB0556 at any time through the first 35 d of infection
when virus titer stabilized at  4   104 GE/ml of plasma
(Fig. 5 B). CD8  T cells were first recovered from a liver
sample collected at day 42 after infection when plasma
viremia abruptly declined to undetectable levels (Fig. 5 B).
These CD8  lymphocytes produced IFN-  in response to
multiple HCV peptide pools and class I epitopes (unpub-
lished data), including the Patr-A0701 restricted epitope
P7756 contained in the core-NS2 peptide pool (Fig. 5 B). A
similar outcome was observed in CB0572 (Fig. 5 C).
CD8  T cells were not recovered from liver until day 28
after infection when a 30-fold reduction in plasma viremia
was observed. They were also HCV-specific, producing
IFN-  in response to the Patr-B2401 restricted epitope
NS52663 (Table II) contained in the NS5 peptide pool (Fig.
5 C). Several HCV peptide pools were recognized at the
next sampling point (day 42 after infection) when virus
was finally cleared from plasma (unpublished data). The
predominant target was a peptide pool containing all struc-
tural proteins (Core-E1-E2-NS2; Fig. 5 C). At least part of
this response targeted the Patr-B2301–restricted epitope
E2445 (Fig. 5 C). HCV-specific CD8  T cells remained in
the liver but were undetectable in the blood of either ani-
mal throughout the entire 6 mo of follow-up (Table III,
Fig. 5 C).
Discussion
Three key features of the memory T cell response against
HCV were revealed by serial infection of chimpanzees
CB0556 and CB0572. First, the frequency of memory
HCV-specific T cells was fixed immediately after resolu-
tion of primary infection. This memory cell set-point did
not vary over a period of several years despite an apparent
absence of virus replication. Second, the response of mem-
ory CD4  and CD8  T cells to reinfection was accelerated
compared with the first infection and coincided with con-
trol of viremia in less than 2 wk. Third and perhaps most
importantly, this rapid antiviral response was lost in the ab-
sence of memory CD8  T cells. The infection was not ter-
minated until this subset recovered in the liver.
Memory CD8  T Cells Alter the Outcome of HCV Infec-
tion. Chronic hepatitis C is uncommon in humans and
chimpanzees who resolved earlier infections with the virus
(17–22). Our studies indicate that CD8  T cells are a criti-
cal component of this protective immunity. HCV-specific
Figure 5. Virus replication and intrahepatic immune responses following antibody-mediated depletion of CD8  T cells. (A) CD4  and CD8  T cell
subsets were monitored in the blood of CB0556 (top panel) and CB0572 (bottom panel) after three doses of cMT-807 (vertical dashed lines). Anti-CD3
expanded CD8  T cells from the liver of CB0556 (B) and CB0572 (C) were tested for IFN-  production in an ELISPOT assay using HCV-1 peptide
pools and individual epitopes. * Indicates inability to recover and expand CD8  T cells from liver tissue until days 42 and 28 after infection from CB0556
(B) and CB0572 (C), respectively. (NS) indicates that no liver sample was obtained from either chimpanzee on day 35 after infection.T
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CTL activity detected in the liver of both chimpanzees as
early as day 10 after infection was kinetically associated
with initial control of viremia. Antibody-mediated deple-
tion of CD8  T cells before a third infection provides di-
rect proof that this lymphocyte subset is important for ter-
mination of HCV replication. Prolonged viral infection in
both CD8  T cell–depleted animals would not have been
predicted from reinfection studies involving animals with
intact immune systems. Indeed, in contrast to the results re-
ported here, the duration and peak of viremia are usually
reduced after successive infections even with different
HCV genotypes (18–22). The importance of CD8  T cells
is further reinforced by the precise temporal relationship
between their recovery in the liver at 4–5 wk and simulta-
neous clearance of HCV RNA from plasma. Our experi-
ments were not designed to address the mechanism by
Table III. Virus Replication and Immune Responses in Blood After CD8 Depletion
CB0556 CB0572
ELISPOT ELISPOT
Day
(after 
infection)
HCV 
RNAa
(GE/ml)
CD8 
T cells/mm3
blood CD8b CD4c Totald
HCV
RNAa
(GE/ml)
CD8 
T cells/mm3
blood CD8b CD4c Totald
 28  50 1,328 125 1,130 4,635  50 1,073 220 145 655
 14 Antibody-mediated depletion of CD8  T cellse Antibody-mediated depletion of CD8  T cellse
 7  50 9 0 1,930 1,110  50 10 0 120 400
0 HCV-1 infection HCV-1 infection
7 48,356 2 0 0 135  50 6 0 980 980
10 41,175 1 0 185 185 543 1 0 0 240
15 31,641 3 0 1,090 835 35,384 8 0 0 0
21 19,373 3 0 875 1,215 24,623 4 0 390 615
28 26,133 5 0 2,225 2,040 760 12 0 1,050 965
35 5,987 4 0 1,685 1,470 234 67 0 420 440
42  50 47 135 1,790 2,330  50 146 0 3,210 3,885
49  50 98 0 3,955 4,900  50 166 0 2,895 3,060
56  50 60 0 2,445 1,670  50 67 0 765 1,085
70  50 61 0 795 915  50 95 0 890 1,545
84  50 70 0 605 685  50 70 0 390 595
112  50 204 0 1,185 1,645  50 69 0 590 410
126  50 139 0 2,040 1,220  50 158 0 705 795
140  50 236 0 2,270 2,390  50 155 0 1,990 3,810
aHCV RNA genome equivalents/ml plasma determined by quantitative TMA assay. Sensitivity of the assay is 50 GE/ml plasma.
bData represent total number of SFCs/106 PBMCs (SFC/106) in response to the dominant CD8 CTL epitopes P7756 and E2445 targeted by CB0556
and CB0572, respectively.
cData represent total number of SFCs/106 PBMCs (depleted of CD8  T cells) in response to all HCV peptide pools.
dData represent total number of SFCs/106 PBMCs (SFC/106) in response to all HCV peptide pools.
eThree doses of the anti-CD8 antibody (cM-T807) were administered on days  14,  11, and  7.
Figure 6. Comparison of virus replication patterns after three consecu-
tive infections of CB0556 and CB0572 with HCV-1.T
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which CD8  T cells control HCV replication. Neverthe-
less, it is noteworthy that liver transaminases did not in-
crease substantially when CD8  T cells finally recovered in
the liver of anti-CD8–treated animals. It is possible that
very few hepatocytes were infected compared with the first
infection so the scale of liver damage by recovering cyto-
toxic T lymphocytes was minimized. On the other hand
we cannot rule out noncytolytic control by IFN-  or other
mechanisms that might silence expression of the HCV
RNA genome in hepatocytes (32, 33). Indeed, clearance of
HCV without an elevation in serum transaminases (2, 4)
but with an increase in liver IFN-  mRNA (2) has been
reported. Furthermore, CD8  T cells were recently shown
to exert noncytolytic control of another hepatotropic virus,
the HBV (26).
It should be emphasized that primed memory CD4  T
cells were present in the blood and liver of both animals af-
ter treatment with anti-CD8 antibodies. Their involve-
ment in control of the third infection is unknown. CD4 
T cells needed to sustain CD8  T cell responses (34) and
helper function(s) might have been especially critical after
anti-CD8 antibody treatment. Effector CD8  T cells prob-
ably expanded from a small memory pool that survived an-
tibody treatment in the liver, and CD4  T cells might have
facilitated recovery by producing growth factors such as IL-2
or by inducing the maturation of antigen presenting cells. It
is also possible that memory CD4  T cells exerted a direct
antiviral effect. We did observe a plateau in virus replica-
tion at levels  10 to 50-fold lower than those measured af-
ter the primary infection of both animals. As noted above,
IFN-  has the potential to inhibit HCV replication and it is
produced in the liver after primary (2) and secondary (22)
HCV infections. Whether IFN-  gene expression is tem-
porally linked to the presence of memory CD4  or CD8 
T cells in the liver of animals treated with anti-CD8 anti-
bodies is being investigated.
Tissue Localization and Phenotypic Markers of Memory T
Cells. Studies in mice revealed that memory T cells can
reside in tissues for long periods of time where they could
provide a rapid first line of defense upon reinfection (30,
31, 35, 36). This may also be true for HCV infection be-
cause our results, although preliminary, indicate that mem-
ory virus-specific CD8  T cells reside in the liver for
months and possibly years after apparent control of viral in-
fection. Anecdotally we were able to establish clonal HCV-
specific CD8  T cells (described in Table II) from the liver
of CB0572 several years after resolution of the primary in-
fection at a time when they were undetectable by either
tetramer staining or CTL killing. At least some of these
populations were localized preferentially to the liver be-
cause they could not be expanded from blood even after
several rounds of stimulation with the cognate peptide (un-
published data).
Corroborative evidence for maintenance of memory
cells in the liver was obtained after the second infection.
Dominant CD8  T cell populations were detected in the
liver by tetramer staining within 1–2 wk of reinfection and
persisted for at least 6 mo after resolution. Memory cell fre-
quencies appeared to be higher in liver than blood and they
were also phenotypically distinct because they constitu-
tively expressed the activation marker CD69 found on tis-
sue resident effector memory T cells in murine models of
infection (30, 31). HCV RNA was not detected in plasma
or liver at multiple time points after resolution of the first
or second infections. We cannot exclude the possibility of
low level virus persistence that contributed to the mainte-
nance of memory T cells. However, we favor the hypothe-
sis that most HCV-specific memory T cells are maintained
in tissues for long periods of time by periodic exposure to
cross-reactive antigens (37) or cytokine-driven homeostatic
proliferation (38).
Functional Memory T Cells Respond Rapidly to Reinfec-
tion. It is important to emphasize that there was no delay
in the response of memory T cells to the second infection.
Memory CD8  T cells with antiviral activity were de-
tected on day 10, only 3 d after HCV RNA was first de-
tected in plasma. Infection was controlled over the next 4 d
and T cells present in blood at the peak of the response
were fully capable of producing IFN-  when stimulated
with antigen. This clearly differs from the prolonged course
of primary infection observed in these animals and reported
for other primary infections of humans and chimpanzees (2,
4). A delay in T cell immunity might be explained, at least
in part, by infection with a hepatotropic virus that is
thought to be noncytopathic. The apparent lack of wide-
spread tissue destruction could delay effective antigen trans-
fer to professional antigen-presenting cells and/or signals
for T cell homing to the site of infection. Effector memory
CD8  T cells residing in the liver could contribute to ac-
celerated immunity upon reinfection by mediating an early
inflammatory response and destruction of infected hepato-
cytes. In support of this mechanism we observed infiltra-
tion of CD8  T cells into the liver parenchyma immedi-
ately after the second infection (unpublished data) and they
exhibited virus-specific CTL activity in vitro. We also can-
not exclude the possibility that HCV selectively interferes
with the efficient generation of primary but not secondary
T cell responses. For instance viral subversion of innate im-
mune responses, or dendritic cell function or maturation,
could have a greater impact on generation of primary but
not secondary T cell responses.
Our data also suggest that virus clearance can be slow
even after induction of HCV-specific T cells during acute
primary hepatitis C. After the first infection of these ani-
mals HCV T cells targeting multiple HCV proteins were
detected in blood on day 56 but viremia was not termi-
nated until 4 to 8 wk later. At least part of this delay in the
effector phase of acute hepatitis C can be attributed to
homing and expansion of T cells in the liver until they
reach a threshold for virus control in this large solid organ.
However, it should also be noted that E2445-specific T cells
failed to make IFN-  when they first appeared in the blood
of CB0572 during the primary infection (Fig. 1 C) but this
effect was transient. In contrast, memory T cells targeting
the same epitope were fully functional through the second
infection and rapidly responded to antigenic stimulation byT
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up-regulation of the activation marker CD69 and produc-
tion of IFN-  (Fig. 2, B and D). This suggests that HCV
can transiently interfere with the activation or differentia-
tion of naive (4, 5, 10–13) but not memory T cells into
functional effector populations.
Features of Protective Immune Responses and Implications for
HCV Vaccines. Both animals in this study were vacci-
nated with recombinant envelope glycoproteins before the
first challenge with HCV. We cannot exclude the possibil-
ity that vaccine-induced antibodies and T cells subtly influ-
enced the outcome of primary infection. Nevertheless, any
protection provided by the vaccine did not match that af-
forded by successful resolution of acute hepatitis C. The
CD4  T cells primed by this vaccine disappeared from the
circulation of both animals after infection, a common fea-
ture of helper cell responses when the virus persists (2, 4, 5,
7, 8). In this instance HCV infection was eventually con-
tained several weeks later when a sustained CD4  and
CD8  T cell response targeting structural and nonstructural
proteins was detected in blood. Memory T cell responses
were maintained in blood and possibly also liver for several
years even though serum antibody titers against HCV pro-
teins were low or undetectable, a profile that has also been
described in humans studied  2 decades after resolution of
infection (39). Rapid control of the second infection in
chimpanzees before a boost in serum anti-envelope anti-
bodies provides evidence that cellular immune responses
alone are sufficient for protection from HCV persistence.
Vaccine approaches focused solely on induction of neutral-
izing antibodies may not be adequate to protect from
chronic infection with viruses that display remarkable ge-
netic diversity in envelope genes. Moreover, the critical
role of CD8  T cells in this process revealed by antibody-
mediated depletion suggests that the same vaccine strategies
for priming CD4  and CD8  T cells to control HIV infec-
tion (40) should also be considered for prevention of HCV
persistence. Where memory CD8  T cells reside might
also be a key factor influencing the rate of HCV clearance
and emergence of class I MHC escape variants (14, 16, 29).
Establishing a repository of memory cells in the liver that
respond rapidly upon reinfection might also enhance vac-
cine-mediated protection against chronic hepatitis C.
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